Case Report
Discovery of an early diagnostic biomarker
Herein we describe the discovery of a small molecule biomarker revealing potential drug targets, and that provides an early diagnostic for NASH by predicting disease development more than 10 years in advance.
Nonalcoholic steatohepatitis (NASH) is a disease for which diagnosis has proven to be challenging, typically requiring MRI-based imaging and/or biopsy of the liver, at which point significant organ damage may have already occurred. Sapient’s client was interested in identifying a circulating diagnostic biomarker that can reveal patients with NASH at a very early stage in their disease process. See the discovery findings below.
Follow Us
